It has been reported that these CD34+/CD38− cells aberrantly expressed elevated levels of AURK that are required for cell cycle progression (21, 22), and targeting AURK demonstrated in vitro efficacy against human Myc-overexpressing AML cells (23). This evidence concerns the gene MYC and acute myeloid leukemia.